Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock
The high-growth semaglutide therapy market, once fueled by an explosive surge in demand, is facing a significant inventory crisis. Following a massive initial rush, a sudden slowdown in sales has left wholesalers and stockists burdened with an estimated ₹100 crore worth of excess stock.
From Explosive Growth to Inventory Overhang
The obesity therapy market, currently valued at approximately ₹2,000 crore, experienced a dramatic shift in momentum between April and May. In April, the market saw a massive spike, with value growth jumping 50% month-on-month and volumes surging by 88%. This frenzy was largely driven by the patent expiry of semaglutide on March 20, which triggered a flood of cheaper generic versions from major Indian pharmaceutical players, including Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals.
However, this rapid influx of supply appears to have outpaced actual consumer demand. In May, the growth momentum stalled significantly, with month-on-month value growth slowing to just 6% and unit growth dropping to 12%. Consequently, stockists and wholesalers are now holding 50–60 days of inventory, a figure that sits well above the industry standard of 30–45 days.
Channel Partners Halt Fresh Procurement
The accumulation of unsold stock has led to a standoff in the supply chain. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that the inventory overhang in the trade channel is valued at nearly ₹100 crore. Due to this glut, channel partners have effectively paused fresh procurement from pharmaceutical manufacturers. Until the existing stocks are liquidated, the flow of new semaglutide products into the retail market is expected to remain stagnant.
Regulatory Hurdles and Competitive Landscape
Industry experts suggest that the sudden moderation in sales may not be purely a supply-demand mismatch but could also be influenced by regulatory shifts. Recent government advisories and prescribing restrictions introduced in April stipulate that GLP-1 receptor agonists should only be prescribed by qualified specialists. This added layer of scrutiny may be slowing down the rapid, widespread adoption seen in earlier months.
Despite the struggles of the semaglutide segment, other therapies in the GLP-1 class continue to perform strongly. Mounjaro (tirzepatide), marketed by Eli Lilly, remained the top-selling therapy in the pharma market during May, with sales increasing by 12% to reach ₹136 crore. This highlights that while generic semaglutide faces an inventory crunch, the broader market for obesity and type 2 diabetes management remains a significant driver within India’s ₹2.5 lakh crore organized pharma retail sector.
Key Takeaways
- Inventory Crisis: The semaglutide trade channel is currently holding an estimated ₹100 crore in excess stock, with inventory levels reaching 50–60 days.
- Growth Slowdown: After an 88% volume surge in April, May saw value growth plummet to just 6% due to a saturated market and paused procurement.
- Regulatory Impact: New guidelines requiring specialists to prescribe GLP-1 therapies are believed to be contributing to the recent slowdown in sales momentum.